BioCentury
ARTICLE | Financial News

Galena Biopharma planning follow-on

December 18, 2012 2:33 AM UTC

Galena Biopharma Inc. (NASDAQ:GALE) said it is planning a follow-on underwritten by Piper Jaffray. Galena's NeuVax is in the Phase III PRESENT trial to prevent recurrence of early stage, node-positive breast cancer. NeuVax is a vaccine comprising an immunogenic peptide derived from epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2; neu) and sargramostim. Galena, which made the announcement after market close, was unchanged at $1.87 on Monday. ...